Authors

Latest:

Dr. Formenti on Combining Radiotherapy With Immunotherapy in NSCLC

Silvia Formenti, MD, chair of Radiation Oncology at Weill Cornell Medical College and radiation oncologist-in-chief at Weill Cornell Medicine and NewYorkPresbyterian Hospital, discusses combining radiotherapy with immunotherapy in non-small cell lung cancer (NSCLC).

Silvia Novello, MD, PhD

Latest:

Dr. Novello on the Gray Areas in Lung Cancer Care

Silvia Novello, MD, PhD, assistant professor, Thoracic Oncology Unit, University of Turin, San Luigi Hospital, Orbassano, Italy, discusses some of the "gray areas" that require more research for the treatment of patients with lung cancer.

Simon Abi aad, MD

Latest:

Our Patients' Care Comes First, Even During Natural Disasters

Simon Abi Aad, MD, discusses caring for patients during Hurricane Irma.

Simon Chowdhury, MA, MBBS, MRCP, PhD

Latest:

Dr. Chowdhury on Separate Roles of Pazopanib and Pembrolizumab in RCC

Simon Chowdhury, MA, MBBS, MRCP, PhD, consultant medical oncologist specializing in urological cancer, Sarah Cannon Research Institute, United Kingdom, discusses what roles pazopanib (Votrient) and pembrolizumab (Keytruda) have as monotherapy for patients with renal cell carcinoma (RCC).

Simon Chowdhury, MD

Latest:

Dr. Chowdhury on Pembrolizumab Plus Pazopanib in RCC

Simon Chowdhury, MD, consultant medical oncologist specializing in urological cancer, Sarah Cannon Research Institute, United Kingdom, discusses the combination of pembrolizumab (Keytruda) and pazopanib (Votrient) in patients with renal cell carcinoma (RCC).

Simon Chowdhury, PhD, MA, MBBS, MRCP

Latest:

Dr. Chowdhury on Sequencing of Immunotherapy Regimens for RCC

Simon Chowdhury, PhD, MA, MBBS, MRCP, consultant medical oncologist specializing in urological cancer, Sarah Cannon Research Institute, United Kingdom, discusses sequencing of immunotherapy regimens for patients with renal cell carcinoma (RCC).

Simon J. Harrison, MBBS, PhD

Latest:

Dr. Harrison on Subcutaneous Daratumumab and Isatuximab in Myeloma

Simon J. Harrison, MBBS, PhD, discusses the impact subcutaneous formulations of daratumumab and isatuximab could have in multiple myeloma.

Simon Murray, MD, Princeton New Jersey

Simon Rule, MD

Latest:

Dr. Rule on the Next Steps for BTK Inhibitors in MCL

Simon Rule, MD, professor of hematology, University of Plymouth, discusses the next steps for ibrutinib (Imbruvica) and other BTK inhibitors in the treatment landscape of mantle cell lymphoma (MCL).

Simon Rule, MD, PhD

Latest:

Dr. Rule on the FDA Approval of Zanubrutinib in MCL

Simon Rule, MD, PhD, professor of hematology, Plymouth University Medical School, United Kingdom, discusses the FDA approval of zanubrutinib (Brukinsa) in mantle cell lymphoma (MCL).

Simron Singh, MD, Odette Cancer Centre

Smita Bhatia, MD

Latest:

Dr. Smita Bhatia on Anthracycline-Related CHF

Smita Bhatia, MD, MPH, Population Sciences, City of Hope, Duarte, California, explains a clinical trial analyzing genetic susceptibility to anthracycline-related congestive heart failure in survivors of hematopoietic cell transplantation.

Smitha Krishnamurthi, MD

Latest:

Dr. Krishnamurthi on CAPTEM as Treatment for Neuroendocrine Tumors

Smitha Krishnamurthi, MD, a medical oncologist and associate professor of medicine at University Hospitals Case Medical Center and Case Western Reserve University, discusses a prospective phase II study of capecitabine and temozolomide (CAPTEM) for progressive, moderately, and well-differentiated metastatic neuroendocrine tumors.

Sneha Phadke, DO

Latest:

Dr Phadke on the Benefit of Sacituzumab Govitecan in HR+/HER2– Breast Cancer

Sneha Phadke, DO, MPH, discusses the benefit associated with treatment consisting of the antibody drug conjugates sacituzumab govitecan in hormone receptor-positive/HER2-negative breast cancer.

Snehal Bhoola, MD

Latest:

Dr. Bhoola on Enhanced Recovery After Surgery in Gynecologic Cancer

Snehal Bhoola, MD, assistant professor, Mercer University School of Medicine, associate professor, University of Arizona, Arizona Oncology, discusses enhanced recovery after surgery (ERAS) in gynecologic malignancies.

Solange Peters, MD, PhD

Latest:

Dr Peters on the Use of Biomarkers to Inform Treatment Decision-Making in NSCLC

Solange Peters, MD, PhD, discusses biomarkers that may inform treatment decision-making prior to immunotherapy use in non–small cell lung cancer.

Solange Peters, MD, PhD, Centre Hospitalier Universitaire Vaudois

Sonali M. Smith, MD

Latest:

Chronic Lymphocytic Leukemia: Emerging Therapeutic Targets

An in-depth review of novel therapeutic targets making their way into clinical trials for patients with chronic lymphocytic leukemia.

Sonali M. Smith, MD, University of Chicago

Sonali Smith, MD

Latest:

Breaking the News in Myeloma, GVHD, and NHL, With Drs Rajkumar, Farhadfar, and Smith

S. Vincent Rajkumar, MD, of Mayo Clinic; Nosha Farhadfar, MD, of Methodist Physician Practices; and Sonali Smith, MD, of University of Chicago Medicine, sit down with Chandler Park, MD, FACP, to discuss the latest in multiple myeloma, graft-vs-host disease, and non-Hodgkin lymphoma, respectively, from the 2024 ASH Annual Meeting.